Vinge has advised the owners of Cellartis in connection with the sale of Cellartis AB to Cellectis S.A., a company listed on NYSE Euronext in Paris. The owners consist of InnovationsKapital among other venture capital investers as well as the company’s founders and employees. Cellartis has developed world-leading products based on pluripotent stem cells. Cellartis and Cellectis will jointly become a world-leading actor within R&D and development of products and services relating to regenerative and medical applications.
The purchase price consists of a cash element of € 16,400,000, and 1,930,000 in newly-issued Cellectis shares.
Vinge’s team primarily consisted of Anders Strid, Fredrik Sonander, Michael Sterner, Johanna Björnum Nyström, Emma Kero Ljungberg and Tove Bremell.
